103 completed, 43 active not recruiting, 37 recruiting, 36 terminated. 150 Phase 2, 111 Phase 1, 16 Phase 3, 4 Phase 4, 3 Not applicable.
Follow trametinib: new trials by email Literature Review of trametinib trials Research Report on trametinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT Trametinib - HCM, Noonan Syndrome and Other Rasopathy | Phase 3 | Not yet recruiting | Carelon Research | 25 | 2027-08-01 | 2026-09-14 |
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-15 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma Methotrexate, Doxorubicin, Cisplatin - Osteosarcoma, Metastasis | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-03-11 | 2026-03-17 |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation XP-102, Trametinib - Cancer, BRAF V600 Mutation | Phase 1 / Phase 2 | Not yet recruiting | Xynomic Pharmaceuticals, Inc. | 221 | 2025-12-31 | 2025-04-10 |
| Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer Multitarget Tyrosine Kinase Inhibitors, BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor - Thyroid Cancer, Thyroid Neoplasms | Recruiting | Fujian Medical University | 120 | 2025-12-23 | 2026-02-19 | |
| Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI) - BRAF V600 Mutation, Low-grade Glioma | Phase 2 | Recruiting | University of California, San Francisco | 96 | 2025-11-07 | 2026-10-22 |
| 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs Trametinib - Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 45 | 2025-08-27 | 2026-10-19 |
| MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. Dabrafenib + Trametinib, Pembrolizumab, Nivolumab - Melanoma, Fertility | Recruiting | Intergruppo Melanoma Italiano | 270 | 2025-08-04 | 2025-09-05 | |
| Trametinib Treatment for Complicated Vascular Anomalies Trametinib tablet - Vascular Anomalies | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 20 | 2025-07-07 | 2025-07-22 |
| Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms | Phase 4 | Not yet recruiting | Fujian Medical University | 335 | 2025-07-01 | 2025-06-08 |
| Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children Dabrafenib or Trametinib and Clofarabine - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Recruiting | West China Second University Hospital | 20 | 2025-06-01 | 2025-06-15 |
| Imatinib and Trametinib for KRAS-mutated Solid Tumor Imatinib, Trametinib - Solid Tumor Cancer | Phase 1 | Recruiting | China Medical University Hospital | 10 | 2025-05-10 | 2025-05-08 |
| MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab - Low Grade Glioma, High Grade Glioma | Phase 1 / Phase 2 | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 27 | 2025-04-01 | 2026-07-10 |
| Precision Cancer Therapy in Rare Cancers Imatinib, Trametinib, Dabrafenib - Rare Malignant Neoplasm | Phase 2 | Recruiting | Oslo University Hospital | 96 | 2025-03-20 | 2025-03-26 |
| Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma Dabrafenib and trametinib (combination) - Ameloblastoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 46 | 2025-03-01 | 2025-02-11 |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors VVD-159642, Sotorasib, Trametinib - Advanced Solid Tumors | Phase 1 | Recruiting | Vividion Therapeutics, Inc. | 220 | 2025-02-25 | 2026-03-18 |
| Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer Biospecimen Collection, Cabozantinib, Computed Tomography - Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 264 | 2024-12-27 | 2026-09-24 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion Olaparib tablet, Temozolomide capsule, Anlotinib - Solid Tumor, Precision Medicine | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 300 | 2024-11-01 | 2024-12-18 |
Showing 20 of 267. Sign in to see all of them.
Melanoma (82) · Neoplasms (48) · Carcinoma, Non-Small-Cell Lung (28) · Colorectal Neoplasms (20) · Neoplasm Metastasis (15) · Multiple Myeloma (14) · Thyroid Neoplasms (14) · Glioma (12) · Hematologic Neoplasms (11) · Pancreatic Neoplasms (11) · Thyroid Carcinoma, Anaplastic (10) · Brain Neoplasms (8) · Lung Neoplasms (7) · Histiocytosis, Langerhans-Cell (6) · Leukemia, Myeloid, Acute (6)
Novartis Pharmaceuticals (37) · GlaxoSmithKline (32) · National Cancer Institute (NCI) (31) · M.D. Anderson Cancer Center (10) · Memorial Sloan Kettering Cancer Center (7) · University of California, San Francisco (5) · Massachusetts General Hospital (4) · Bristol-Myers Squibb (3) · Jonsson Comprehensive Cancer Center (3) · Melanoma Institute Australia (3) · The Netherlands Cancer Institute (3) · Universitair Ziekenhuis Brussel (3) · University Health Network, Toronto (3) · Cancer Research UK (2) · Centre Leon Berard (2)
United States (163) · France (42) · Canada (37) · Australia (31) · Spain (31) · Italy (30) · Germany (29) · United Kingdom (28) · Belgium (25) · Netherlands (25) · China (20) · South Korea (18) · Japan (16) · Sweden (14) · Argentina (13)
Arthur Frankel, MD (2) · Collin Blakely, MD, PhD (2) · Eric Sherman, MD (2) · Jason J Luke (2) · Philippe Bedard, M.D. (2) · Rodabe N Amaria (2) · Ryan J Sullivan (2) · A P Chen (1) · Adil Daud, M.D. (1) · Alain Algazi, MD (1) · Alain P Algazi (1)
PMID 34225229, PMID 27864013, PMID 34331515, PMID 31166680, PMID 33587894, PMID 36648215, PMID 36884302, PMID 37219859, PMID 37934000, PMID 40148035, PMID 15049016, PMID 18623218, PMID 19731321, PMID 22663011, PMID 23248257, PMID 23255383, PMID 23589673, PMID 23645591, PMID 23893461, PMID 24252784, PMID 24504441, PMID 24577748, PMID 24606567, PMID 24915778, PMID 24983357, PMID 25092772, PMID 25265492, PMID 25287827, PMID 25344362, PMID 25399551, PMID 25411413, PMID 25417902, PMID 25722381, PMID 25794603, PMID 25797743, PMID 26037941, PMID 26194764, PMID 26259955, PMID 26340744, PMID 26392102, PMID 26433819, PMID 26446943, PMID 26586415, PMID 26602013, PMID 26811525, PMID 27080216, PMID 27124486, PMID 27172483, PMID 27223498, PMID 27283860
U10CA180820 (8), 2016 (6), 2023 (6), U01CA062490 (5), U24CA196172 (5), UM1CA186709 (5), 2018 (4), U10CA180888 (4), UM1CA186712 (4), 2015 (3), 2017 (3), P30CA006516 (3), P30CA016672 (3), U10CA032102 (3), 2019 (2)